Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Cardiology

The Lifeline: Understanding Your Post-Heart Attack Medications

At a Glance

After a heart attack, antiplatelet medicines help prevent clots, statins lower LDL cholesterol and stabilize plaque, and other drugs may protect heart function. The combination and duration depend on your stent, bleeding risk, heart function, kidney health, diabetes, and LDL level.

Surviving a heart attack is the first step; the next is committing to “secondary prevention”—using medications to prevent a second event. These drugs are not optional supplements; they are essential tools that physically change how your blood clots, how your heart heals, and how your arteries handle cholesterol [1][2]. Some are prescribed for a specific period, while others may be lifelong.

Dual Antiplatelet Therapy (DAPT): Preventing Clots

A critical set of medications you may take are your antiplatelets, often prescribed as Dual Antiplatelet Therapy (DAPT). This is commonly a combination of aspirin and a second drug (usually clopidogrel, ticagrelor, or prasugrel) [1]. Note that antiplatelets are a different class of drugs than anticoagulants (like warfarin or Eliquis).

  • The Purpose: These drugs prevent blood cells (platelets) from sticking together and forming a clot inside your new stent or in other narrowed arteries [1].
  • The Duration: A common default duration for DAPT after an acute coronary syndrome is 12 months [1][3]. However, your doctor may shorten this to 1–3 months if you have a high risk of bleeding or require oral anticoagulants, or lengthen it if your risk is very high [4][5]. (For Type 2 MI or MINOCA, DAPT is not automatic and is highly individualized.)
  • A Life-Saving Rule: Do not stop or change your DAPT without urgent advice from your cardiology team. Stopping early significantly increases the risk of stent thrombosis—a sudden, life-threatening clot inside your stent [6]. In the event of major bleeding or a surgical emergency, the treating clinicians will decide the safest path. If you miss a dose, follow your prescriber’s specific instructions.

Lipid Management

To stabilize existing plaques (fatty buildups) and lower your cardiovascular risk, you will likely be prescribed a high-intensity statin (such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg) [7].

  • The Target: Some international secondary-prevention guidelines recommend aiming for an LDL cholesterol target below 55 mg/dL for very-high-risk patients, though your clinician will set your specific goal [8].
  • The 50% Rule: Clinicians often want to see at least a 50% reduction from your baseline LDL level with high-intensity therapy [8][7].
  • Beyond Statins: If statins alone don’t reach your target, your doctor may add ezetimibe or injectable medications called PCSK9 inhibitors [9][10].

Protecting the Heart Muscle

Several other classes of medication help your heart pump more efficiently and reduce the “workload” it faces during recovery.

ACE Inhibitors and ARBs

Drugs like lisinopril (ACE inhibitors) or losartan (ARBs) help relax blood vessels and lower blood pressure. They are most important if your heart’s pumping strength (LVEF) is 40% or lower, or if you have specific conditions like heart failure, kidney disease, or diabetes—though this depends on your renal function and potassium levels [11][12]. Your care team will monitor your kidney function and potassium. A common side effect of ACE inhibitors is a dry, hacking cough; if this happens, your doctor can switch you to an ARB [13].

Beta-Blockers

Beta-blockers (like metoprolol or carvedilol) slow your heart rate and lower your blood pressure, giving your heart muscle more time to rest between beats [11]. While they are vital for patients with reduced heart function, angina, or arrhythmias, recent research suggests they may not be needed indefinitely for patients with normal heart function and no other issues [14]. Common side effects include fatigue or feeling “slowed down” [15]. Do not stop them abruptly without clinician advice.

SGLT2 Inhibitors

SGLT2 inhibitors (like dapagliflozin or empagliflozin) are commonly indicated for specific patients with diabetes, chronic kidney disease, or heart failure [16]. They are not universally required for every heart attack survivor. They help the body get rid of excess salt and water [17]. It is important to stay hydrated while taking these, watch for signs of volume depletion (low blood pressure/dizziness), maintain genital hygiene to prevent infections, and be aware of a rare risk of euglycemic ketoacidosis [18][19]. Follow your prescriber’s instructions regarding holding the medication during severe illness, prolonged fasting, or before surgery.

Managing Your Medications

These medications work as a team. If you experience side effects—such as muscle aches from statins or dizziness from blood pressure meds—contact your care team rather than self-adjusting [20].

  1. Note the symptom: When did it start? How severe is it?
  2. Call your team: Most side effects can be managed safely by adjusting the dose or switching to a different drug in the same class.
  3. Monitor at home: Keep a log of your blood pressure and heart rate to show your doctor at follow-up visits [20]. This data helps them “fine-tune” your doses for maximum protection with the fewest side effects.

Common questions in this guide

How long will I be on two antiplatelet medicines after my heart attack?
After an acute coronary syndrome, two antiplatelet medicines are commonly continued for about 12 months. Your cardiology team may shorten treatment to one to three months or extend it based on bleeding risk, clot risk, a stent, other blood thinners, and the type of heart attack. It is not automatically needed after every kind of heart attack.
What should I do about aspirin if I need dental work or surgery?
Do not stop aspirin or the second antiplatelet on your own, especially if you have a stent. Contact your cardiology team before dental work or surgery so your clinicians can balance bleeding risk against the risk of a clot forming in the stent.
What LDL cholesterol result should I aim for after a heart attack?
Your clinician will set an individual LDL cholesterol goal, but some guidelines for people at very high risk recommend a level below 55 mg/dL. High-intensity statins often aim to reduce LDL by at least 50%; ezetimibe or an injectable PCSK9 inhibitor may be added if the goal is not reached.
How does heart pumping strength affect my need for ACE inhibitors and beta-blockers?
ACE inhibitors and ARBs relax blood vessels and are especially important when the heart pumps less strongly or when heart failure, kidney disease, or diabetes is present. Beta-blockers slow the heart and are particularly useful with reduced heart function, angina, or an abnormal rhythm, although some people with normal heart function may not need them indefinitely. Your clinician uses your heart function, kidney function, potassium level, and other conditions to choose the plan.
Are SGLT2 inhibitors recommended for every heart attack survivor?
No. SGLT2 inhibitors are generally prescribed for selected people with diabetes, chronic kidney disease, or heart failure, not automatically for every heart attack survivor. Ask your prescriber when to hold the medicine during severe illness, prolonged fasting, or before surgery, and seek advice if you become very dizzy or dehydrated.
How can I tell whether a medication side effect needs a call to my doctor?
Contact your care team rather than changing the dose or stopping the medicine yourself. Note when symptoms such as muscle aches, a persistent cough, unusual fatigue, bruising, or dizziness began, and record your blood pressure and heart rate so the clinician can adjust treatment safely.
What is the difference between antiplatelets and anticoagulants?
Antiplatelets, such as aspirin and clopidogrel, reduce the tendency of platelets to stick together and are often used to protect a stent. Anticoagulants, such as warfarin or Eliquis, act on different clotting proteins; they are not interchangeable and should only be combined with antiplatelets when prescribed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my heart attack type, stent, and bleeding risk, how long should I expect to be on dual antiplatelet therapy (DAPT)?
  2. 2.What is my target LDL cholesterol number, and when should we re-check my levels to see if the statin is working?
  3. 3.Do I have 'reduced' or 'preserved' heart function (LVEF), and how does that affect my need for beta-blockers and ACE inhibitors?
  4. 4.Is an SGLT2 inhibitor appropriate for me based on my specific kidney health, heart function, or diabetes status?
  5. 5.What should I do if I notice unusual bruising, or if I feel too dizzy to stand up quickly?
  6. 6.If I need a dental procedure or another surgery, who should I contact before stopping any of my antiplatelet medications?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Early discontinuation of acetylsalicylic acid after angioplasty in acute coronary syndromes: the NEO-MINDSET and TARGET-FIRST studies.

    Di Leo G, Nastasi D, Capodanno D

    European heart journal supplements : journal of the European Society of Cardiology 2026; (28(Suppl 5)):v62-v67 doi:10.1093/eurheartjsupp/suag027.

    PMID: 42099471
  2. 2

    Antithrombotic treatment in primary percutaneous coronary intervention.

    Voll F, Kuna C, Ndrepepa G, et al.

    Expert review of cardiovascular therapy 2021; (19(4)):313-324 doi:10.1080/14779072.2021.1902807.

    PMID: 33705211
  3. 3

    Antiplatelet therapy in acute coronary syndrome: a systematic critical appraisal of current guidelines.

    Xing Y, Bai C, Chen S, et al.

    BMC cardiovascular disorders 2026; (26(1)).

    PMID: 42067803
  4. 4

    Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field.

    De Servi S, Landi A, Savonitto S, et al.

    Journal of clinical medicine 2023; (12(5)) doi:10.3390/jcm12052082.

    PMID: 36902869
  5. 5

    [Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?]

    Darius H

    Der Internist 2021; (62(11)):1243-1252 doi:10.1007/s00108-021-01189-5.

    PMID: 34633479
  6. 6

    Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.

    Guimarães PO, Franken M, Tavares CAM, et al.

    The New England journal of medicine 2025; (393(21)):2095-2106 doi:10.1056/NEJMoa2507980.

    PMID: 40888723
  7. 7

    High-intensity versus very-high-intensity statin, both on top of ezetimibe, in acute myocardial infarction: A pragmatic randomized study.

    Chiusolo S, Masini G, Zywicki V, et al.

    International journal of cardiology 2026; (448()):134140 doi:10.1016/j.ijcard.2025.134140.

    PMID: 41519389
  8. 8

    Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.

    Allahyari A, Jernberg T, Hagström E, et al.

    European heart journal 2020; (41(40)):3900-3909 doi:10.1093/eurheartj/ehaa034.

    PMID: 32072178
  9. 9

    Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

    Cannon CP, Blazing MA, Giugliano RP, et al.

    The New England journal of medicine 2015; (372(25)):2387-97 doi:10.1056/NEJMoa1410489.

    PMID: 26039521
  10. 10

    Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.

    Mehta SR, Pare G, Lonn EM, et al.

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2022; (18(11)):e888-e896 doi:10.4244/EIJ-D-22-00735.

    PMID: 36349701
  11. 11

    Post-Myocardial Infarction Heart Failure.

    Bahit MC, Kochar A, Granger CB

    JACC. Heart failure 2018; (6(3)):179-186 doi:10.1016/j.jchf.2017.09.015.

    PMID: 29496021
  12. 12

    ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.

    Sobhy M, Eletriby A, Ragy H, et al.

    Cardiology and therapy 2024; (13(4)):707-736 doi:10.1007/s40119-024-00381-6.

    PMID: 39455534
  13. 13

    Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials.

    Shunan F, Jiqing Y, Xue D

    Journal of the renin-angiotensin-aldosterone system : JRAAS 2018; (19(4)):1470320318803495 doi:10.1177/1470320318803495.

    PMID: 30296880
  14. 14

    Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.

    Ibanez B, Latini R, Rossello X, et al.

    The New England journal of medicine 2025; (393(19)):1889-1900 doi:10.1056/NEJMoa2504735.

    PMID: 40888702
  15. 15

    Routine beta-blocker therapy after acute coronary syndromes: The end of an era?

    Johner N, Gencer B, Roffi M

    European journal of clinical investigation 2024; (54(12)):e14309 doi:10.1111/eci.14309.

    PMID: 39257189
  16. 16

    Patterns in Prescribing and Predictors of SGLT2 Inhibitor Administration in Patients with Heart Failure and Acute Myocardial Infarction: A Real-World Retrospective Cohort Study.

    Suciu IM, Mateoc-Sîrb T, Luca CT, et al.

    Journal of clinical medicine 2026; (15(3)) doi:10.3390/jcm15031056.

    PMID: 41682737
  17. 17

    Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.

    Usman MS, Siddiqi TJ, Anker SD, et al.

    Journal of the American College of Cardiology 2023; (81(25)):2377-2387 doi:10.1016/j.jacc.2023.04.034.

    PMID: 37344038
  18. 18

    In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure.

    Arshad MS, Jamil A, Greene SJ, et al.

    Heart failure reviews 2025; (30(1)):89-101 doi:10.1007/s10741-024-10446-2.

    PMID: 39404914
  19. 19

    SGLT2 inhibitor-associated euglycemic ketoacidosis after percutaneous coronary intervention for ST-segment elevation myocardial infarction.

    Kuno T, Amanai S, Takama N, Ishii H

    Journal of cardiology cases 2026; (33(2)):37-39 doi:10.1016/j.jccase.2025.10.002.

    PMID: 41732394
  20. 20

    Applications of SGLT2 inhibitors beyond glycaemic control.

    O'Hara DV, Lam CSP, McMurray JJV, et al.

    Nature reviews. Nephrology 2024; (20(8)):513-529 doi:10.1038/s41581-024-00836-y.

    PMID: 38671190

This page explains medicines commonly used after an acute myocardial infarction for informational purposes only and does not constitute medical advice. Do not stop or change any prescription without guidance from your cardiology team.

Get notified when new evidence is published on acute myocardial infarction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.